Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Fig. 2

The combination of temozolomide (TMZ) and SKI-II potentiates death in GB cells. NCH82 cells were analyzed by flow cytometry after treatment with vehicle control (DMSO), 48 µM TMZ, 2.66 µM SKI-II, and the combination (TMZ + SKI-II) in the presence and absence of 20 µM zVAD-fmk (zVAD) for 3 and 5 days, under normoxia (21% O2) and hypoxia (3% O2). A Applied quadrant in propidium iodide- (PI) and AnnexinV (AV)-FITC-stained NCH82 cells. B-E Quantification of PI- and AV-FITC-labeled NCH82 cells. Data represent mean + SD of n = 3. Flow cytometry data analysis was performed using the software FlowJo. One-way ANOVA followed by Tukey’s multiple comparisons test was performed for statistical analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us